Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of Twist and E-cadherin in patients with osteosarcoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Twist, a basic helix-loop-helix transcription factor, and E-cadherin are both correlated with the metastatic progression of several types of cancer. However, it is currently unknown whether their activations have relevance to the progression of osteosarcoma. The purpose of the present study was to investigate the clinicopathological and prognostic value of Twist and E-cadherin in osteosarcoma. Twist and E-cadherin expressions were determined by immunohistochemistry. Patient survival rates were determined by Kaplan–Meier method and log-rank test. Cox regression was adopted for multivariate analysis of prognostic factors. The positive rates of Twist and E-cadherin in 107 osteosarcoma specimens were 31.8 % (34/107) and 20.6 % (22/107), respectively. Twist expression was significantly correlated with that of E-cadherin (r = −0.209, P = 0.031). The positive expression of Twist and E-cadherin was significantly associated with metastasis in 107 osteosarcoma specimens (both P < 0.05). Patients with positive Twist expression had significantly poorer overall survival (OS; P < 0.05) and disease-free survival (DFS, P < 0.05) when compared with patients with the negative expression of Twist. Patients with positive expression of E-cadherin had significantly poorer OS (P < 0.05) when compared with patients with negative E-cadherin expression, but not a significantly poorer DFS (P = 0.081). On multivariate analysis, Twist expression and age were found to be independent prognostic factors for OS (both P < 0.05) and DFS (both P < 0.05). Our results suggest that Twist was expressed significantly more and E-cadherin significantly less in osteosarcoma with metastasis, and expression of both might be related to the prediction of metastasis potency and poor prognosis for patients with osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yao Y, Dong Y, Lin F, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 2009;21(1):229–35.

    PubMed  CAS  Google Scholar 

  2. Jaffe N. Adjuvant chemotherapy in osteosarcoma: an odyssey of rejection and vindication. Cancer Treat Res. 2009;152:219–37.

    Article  PubMed  Google Scholar 

  3. Thisse B, El Messal M, Perrin-Schmitt F. The twist gene: isolation of a Drosophila zygotic gene necessary for the establishment of dorsoventral pattern. Nucleic Acids Res. 1987;15(8):3439–53.

    Article  PubMed  CAS  Google Scholar 

  4. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–39.

    Article  PubMed  CAS  Google Scholar 

  5. Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell–cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113(1):173–85.

    Article  PubMed  CAS  Google Scholar 

  6. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153(2):333–9.

    Article  PubMed  CAS  Google Scholar 

  7. Castilla MA, Moreno-Bueno G, Romero-Perez L, et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 2011;223(1):72–80.

    Article  PubMed  CAS  Google Scholar 

  8. Kwok WK, Ling MT, Lee TW, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005;65(12):5153–62.

    Article  PubMed  CAS  Google Scholar 

  9. Niu RF, Zhang L, Xi GM, et al. Up-regulation of Twist induces angiogenesis and correlates with metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2007;26(3):385–94.

    PubMed  CAS  Google Scholar 

  10. Yuen HF, Chan YP, Wong ML, et al. Upregulation of twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol. 2007;60(5):510–4.

    Article  PubMed  CAS  Google Scholar 

  11. Shin HW, Cho K, Kim DW, et al. Hypoxia-inducible factor 1 mediates nasal polypogenesis by inducing epithelial-to-mesenchymal transition. Am J Respir Crit Care Med. 2012;185(9):944–54.

    Article  PubMed  CAS  Google Scholar 

  12. Maestro R, Dei TAP, Hamamori Y, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999;13(17):2207–17.

    Article  PubMed  CAS  Google Scholar 

  13. Hao L, Ha JR, Kuzel P, Garcia E, Persad S. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3 K/PTEN pathway through Twist and Snail. Br J Dermatol. 2012;166(6):1184–97.

    Article  PubMed  CAS  Google Scholar 

  14. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–90.

    Article  PubMed  Google Scholar 

  15. Paznekas WA, Cunningham ML, Howard TD, et al. Genetic heterogeneity of Saethre-Chotzen syndrome, due to TWIST and FGFR mutations. Am J Hum Genet. 1998;62(6):1370–80.

    Article  PubMed  CAS  Google Scholar 

  16. Xue G, Hemmings BA. Phosphorylation of basic helix-loop-helix transcription factor twist in development and disease. Biochem Soc Trans. 2012;40(1):90–3.

    Article  PubMed  CAS  Google Scholar 

  17. Qin Q, Xu Y, He T, Qin C, Xu J. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 2012;22(1):90–106.

    Article  PubMed  CAS  Google Scholar 

  18. Entz-Werle N, Stoetzel C, Berard-Marec P, et al. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer. 2005;117(3):349–55.

    Article  PubMed  CAS  Google Scholar 

  19. Entz-Werle N, Lavaux T, Metzger N, et al. Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia. 2007;9(8):678–88.

    Article  PubMed  CAS  Google Scholar 

  20. Entz-Werle N, Choquet P, Neuville A, et al. Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease. Transl Oncol. 2010;3(6):344–53.

    PubMed  Google Scholar 

  21. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell. 2004;6(6):625–30.

    Article  PubMed  CAS  Google Scholar 

  22. Yang MH, Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle. 2008;7(14):2090–6.

    Article  PubMed  CAS  Google Scholar 

  23. Guo Y, Xie J, Rubin E, et al. Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res. 2008;68(9):3350–60.

    Article  PubMed  CAS  Google Scholar 

  24. Ding J, Zhang Z, Pan Y, Liao G, Zeng L, Chen S. Expression and significance of twist, e-cadherin, and n-cadherin in gastrointestinal stromal tumors. Dig Dis Sci. 2012. doi:10.1007/s10620-012-2186-4.

  25. Fassina A, Cappellesso R, Guzzardo V, et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 2012;25(1):86–99.

    Article  PubMed  CAS  Google Scholar 

  26. Kawanishi J, Kato J, Sasaki K, Fujii S, Watanabe N, Niitsu Y. Loss of E-cadherin-dependent cell–cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol. 1995;15(3):1175–81.

    PubMed  CAS  Google Scholar 

  27. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci. 1999;24(2):73–6.

    Article  PubMed  CAS  Google Scholar 

  28. Shino Y, Watanabe A, Yamada Y, et al. Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer. 1995;76(11):2193–201.

    Article  PubMed  CAS  Google Scholar 

  29. Gabbert HE, Mueller W, Schneiders A, et al. Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int J Cancer. 1996;69(3):184–9.

    Article  PubMed  CAS  Google Scholar 

  30. Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 2000;60(2):298–304.

    PubMed  CAS  Google Scholar 

  31. Eckert MA, Yang J. Targeting invadopodia to block breast cancer metastasis. Oncotarget. 2011;2(7):562–8.

    PubMed  Google Scholar 

  32. Yonemura Y, Nojima N, Kaji M, et al. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer. 1995;76(6):941–53.

    Article  PubMed  CAS  Google Scholar 

  33. Shun CT, Wu MS, Lin JT, et al. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer. Hepatogastroenterology. 1998;45(22):944–9.

    PubMed  CAS  Google Scholar 

  34. Yonemura Y, Endou Y, Kimura K, et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res. 2000;6(11):4234–42.

    PubMed  CAS  Google Scholar 

  35. Uchikado Y, Okumura H, Ishigami S, et al. Increased Slug and decreased E-cadherin expression is related to poor prognosis in patients with gastric cancer. Gastric Cancer. 2011;14(1):41–9.

    Article  PubMed  CAS  Google Scholar 

  36. Kashima T, Nakamura K, Kawaguchi J, et al. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer. 2003;104(2):147–54.

    Article  PubMed  CAS  Google Scholar 

  37. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548–58.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Dr Yongbing Hu and Yahui Huang for their assistance with the evaluation of immunohistochemical staining.

Conflict of interest

All authors declared no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Orthopaedics, Xiangya Hospital, Central South University, # 87 Xiangya Road, Changsha, 410008, Hunan, China

    Ke Yin, Qiande Liao, Hongbo He & Da Zhong

  2. Department of Orthopaedics, Affiliated Nanhua Hospital, South China University, #336 Dongfeng South Road, Hengyang, 421008, Hunan, China

    Ke Yin

Authors
  1. Ke Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiande Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongbo He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Da Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiande Liao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yin, K., Liao, Q., He, H. et al. Prognostic value of Twist and E-cadherin in patients with osteosarcoma. Med Oncol 29, 3449–3455 (2012). https://doi.org/10.1007/s12032-012-0317-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0317-6

Keywords

Search

Navigation